By Clinical Informatics News Staff

January 4, 2017 | INC Research and inVentiv Health, which merged in August have announced a new name: Syneos Health, Inc. The merger, announced last May and made final in August, combined Contract Research Organization (CRO) and Contract Commercial Organization (CCO) capabilities. Now Syneos Health (https://www.syneoshealth.com/) claims to be the only fully integrated, end-to-end biopharmaceutical solutions organization.

The word Syneos (pronounced SIN-ee-ohs) is meant to encompass the value of synchronizing clinical and commercial capabilities to accelerate customer performance and “neo,” signaling a new approach to problem-solving and a new biopharmaceutical solutions category for the healthcare workforce. Syneos Health solutions are fully integrated—sharing knowledge, data and insights—to deliver better processes and smarter practices to speed the delivery of biopharmaceutical therapies to market.

“Syneos Health fully expresses our value proposition—that is, our ability to deliver integrated end-to-end solutions and create new paths for our customers to develop and commercialize their therapies,” said Alistair Macdonald, Chief Executive Officer of Syneos Health and former CEO of INC Research, in a statement announcing the new identity. “Unlike traditional CROs and commercialization businesses, we are knocking down walls and enabling clinical and commercial experts to work in sync by using the latest technologies, advanced business practices and the advantages of scale. Our Biopharmaceutical Acceleration Model is unique to the industry, and from this ambitious vision, Syneos Health was born.”

The company’s platform includes clinical and commercial solutions. For example, behavioral insights are leveraged to accelerate clinical trial recruitment, and therapeutic know-how infuses multi-channel commercial programs to better engage increasingly hard-to-reach stakeholders. All of these solutions are designed to improve the likelihood of launch success.

In connection with the name change, Syneos Health common shares are expected to trade on the Nasdaq Global Select Market under the new ticker symbol “SYNH” by January 9, 2018. Until then, Syneos Health will continue to be listed under INC Research Holdings, Inc. and the symbol “INCR.”